$ACT Recent News 10 S&P 500 companies with the
Post# of 94145
Posted On: 11/11/2014 10:00:01 AM
$ACT Recent News
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Today - Philip van Doorn
Ackman urges Allergan to open sale process, negotiate 10:33 a.m. Nov. 7, 2014 - Chelsey Dulaney
Actavis sales surge, exceed forecasts 7:51 a.m. Nov. 5, 2014 - MarketWatch.com
Media, consumer-based company earnings to test stock rally 4:30 a.m. Nov. 2, 2014 - Wallace Witkowski
Pfizer sales fall less than expected 7:34 a.m. Oct. 28, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
Small-cap buckling and trap doors could make for a brutal earnings season 6:07 a.m. Oct. 8, 2014 - Shawn Langlois
Valeant to boost Allergan bid by $15 a share: report 5:48 p.m. Oct. 7, 2014 - Russ Britt
Actavis agrees to acquire Durata Therapeutics 8:44 a.m. Oct. 6, 2014 - Tess Stynes
Pharma love triangle is a win, win, win for investors 1:11 p.m. Oct. 2, 2014 - The Trading Deck
In focus: Finally, a breakdown 7:40 p.m. Oct. 1, 2014 - Lawrence G. McMillan
In focus: Back in the trading range 2:26 p.m. Sept. 24, 2014 - Lawrence G. McMillan
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Actavis's Salix play undermines Allergan defense 11:43 a.m. Sept. 24, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:42 a.m. Sept. 24, 2014 - Russ Britt
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Botox maker Allergan rejected Actavis takeover bid 6:18 p.m. Sept. 22, 2014 - Jonathan D. Rockoff
In focus: Market giving mixed signals 7:02 p.m. Sept. 17, 2014 - Lawrence G. McMillan
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis Says 'Let's Make A Deal' 17 min ago - Seeking Alpha
Actavis (ACT) Upgraded From Hold to Buy 54 min ago - TheStreet.com
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio 5:16 p.m. Nov. 9, 2014 - GuruFocus.com
Ackman Calls for Auction of Allergan 3:38 p.m. Nov. 7, 2014 - The Wall Street Journal Interactive Edition
3 Stocks Dragging In The Drugs Industry 12:06 p.m. Nov. 7, 2014 - TheStreet.com
Comparing America's 3 Largest Generic Drugs Companies 10:05 a.m. Nov. 7, 2014 - Seeking Alpha
Salix Shares Plunge on Accounting Revision 8:57 p.m. Nov. 6, 2014 - The Wall Street Journal Interactive Edition
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog 1:20 p.m. Nov. 6, 2014 - Zacks.com
Company News for November 06, 2014 - Corporate Summary 10:10 a.m. Nov. 6, 2014 - Zacks.com
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid 9:25 a.m. Nov. 6, 2014 - TheStreet.com
Deutsche Bank’s U.S. Stock Selection Best Buy Ideas 7:43 a.m. Nov. 6, 2014 - 247WallSt.com
Jim Cramer's Top Stock Picks: LMT MPC ACT 6:00 a.m. Nov. 6, 2014 - TheStreet.com
Cramer's Mad Money - Actavis, What A Stock (11/5/14) 5:57 a.m. Nov. 6, 2014 - Seeking Alpha
2 Biotech Stocks to Buy After Earnings 5:45 a.m. Nov. 6, 2014 - InvestorPlace.com
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks 8:20 p.m. Nov. 5, 2014 - TheStreet.com
10-Q: ACTAVIS PLC 5:06 p.m. Nov. 5, 2014 - Edgar Online - (EDG = 10Q, 10K)
Actavis (ACT) Earnings Report: Q3 2014 Conference Call Transcript 2:10 p.m. Nov. 5, 2014 - TheStreet.com
3 IBD 50 Tech, Drug Stocks With Earnings Thursday 1:49 p.m. Nov. 5, 2014 - Investors Business Daily
Actavis' (ACT) CEO Brent Saunders on Q3 2014 Results - Earnings Call Transcript 1:29 p.m. Nov. 5, 2014 - Seeking Alpha
Actavis Beats Q3 Estimates As Buyout Talk Swirls 10:07 a.m. Nov. 5, 2014 - Investors Business Daily
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 6:45 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 6:30 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4:15 p.m. Oct. 31, 2014 - PR Newswire - PRF
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
Actavis Confirms Generic Quillivant XR® Patent Challenge 8:00 a.m. Oct. 16, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting 8:00 a.m. Oct. 9, 2014 - BusinessWire - BZX
EQUITY ALERT: Rosen Law Firm Announces Investigation of Durata Therapeutics, Inc. Concerning its Proposed Sale to Actavis plc – DRTX 11:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 11:34 a.m. Oct. 6, 2014 - PR Newswire - PRF
Actavis to Acquire Durata Therapeutics, Inc. 8:00 a.m. Oct. 6, 2014 - PR Newswire - PRF
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents 7:30 a.m. Oct. 2, 2014 - GlobeNewswire
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast 8:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Actavis Confirms Generic Butrans® Patent Challenge 4:05 p.m. Sept. 25, 2014 - PR Newswire - PRF
10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Today - Philip van Doorn
Ackman urges Allergan to open sale process, negotiate 10:33 a.m. Nov. 7, 2014 - Chelsey Dulaney
Actavis sales surge, exceed forecasts 7:51 a.m. Nov. 5, 2014 - MarketWatch.com
Media, consumer-based company earnings to test stock rally 4:30 a.m. Nov. 2, 2014 - Wallace Witkowski
Pfizer sales fall less than expected 7:34 a.m. Oct. 28, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
Small-cap buckling and trap doors could make for a brutal earnings season 6:07 a.m. Oct. 8, 2014 - Shawn Langlois
Valeant to boost Allergan bid by $15 a share: report 5:48 p.m. Oct. 7, 2014 - Russ Britt
Actavis agrees to acquire Durata Therapeutics 8:44 a.m. Oct. 6, 2014 - Tess Stynes
Pharma love triangle is a win, win, win for investors 1:11 p.m. Oct. 2, 2014 - The Trading Deck
In focus: Finally, a breakdown 7:40 p.m. Oct. 1, 2014 - Lawrence G. McMillan
In focus: Back in the trading range 2:26 p.m. Sept. 24, 2014 - Lawrence G. McMillan
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Actavis's Salix play undermines Allergan defense 11:43 a.m. Sept. 24, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:42 a.m. Sept. 24, 2014 - Russ Britt
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Botox maker Allergan rejected Actavis takeover bid 6:18 p.m. Sept. 22, 2014 - Jonathan D. Rockoff
In focus: Market giving mixed signals 7:02 p.m. Sept. 17, 2014 - Lawrence G. McMillan
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky
Actavis Says 'Let's Make A Deal' 17 min ago - Seeking Alpha
Actavis (ACT) Upgraded From Hold to Buy 54 min ago - TheStreet.com
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio 5:16 p.m. Nov. 9, 2014 - GuruFocus.com
Ackman Calls for Auction of Allergan 3:38 p.m. Nov. 7, 2014 - The Wall Street Journal Interactive Edition
3 Stocks Dragging In The Drugs Industry 12:06 p.m. Nov. 7, 2014 - TheStreet.com
Comparing America's 3 Largest Generic Drugs Companies 10:05 a.m. Nov. 7, 2014 - Seeking Alpha
Salix Shares Plunge on Accounting Revision 8:57 p.m. Nov. 6, 2014 - The Wall Street Journal Interactive Edition
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog 1:20 p.m. Nov. 6, 2014 - Zacks.com
Company News for November 06, 2014 - Corporate Summary 10:10 a.m. Nov. 6, 2014 - Zacks.com
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid 9:25 a.m. Nov. 6, 2014 - TheStreet.com
Deutsche Bank’s U.S. Stock Selection Best Buy Ideas 7:43 a.m. Nov. 6, 2014 - 247WallSt.com
Jim Cramer's Top Stock Picks: LMT MPC ACT 6:00 a.m. Nov. 6, 2014 - TheStreet.com
Cramer's Mad Money - Actavis, What A Stock (11/5/14) 5:57 a.m. Nov. 6, 2014 - Seeking Alpha
2 Biotech Stocks to Buy After Earnings 5:45 a.m. Nov. 6, 2014 - InvestorPlace.com
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks 8:20 p.m. Nov. 5, 2014 - TheStreet.com
10-Q: ACTAVIS PLC 5:06 p.m. Nov. 5, 2014 - Edgar Online - (EDG = 10Q, 10K)
Actavis (ACT) Earnings Report: Q3 2014 Conference Call Transcript 2:10 p.m. Nov. 5, 2014 - TheStreet.com
3 IBD 50 Tech, Drug Stocks With Earnings Thursday 1:49 p.m. Nov. 5, 2014 - Investors Business Daily
Actavis' (ACT) CEO Brent Saunders on Q3 2014 Results - Earnings Call Transcript 1:29 p.m. Nov. 5, 2014 - Seeking Alpha
Actavis Beats Q3 Estimates As Buyout Talk Swirls 10:07 a.m. Nov. 5, 2014 - Investors Business Daily
Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 6:45 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 6:30 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4:15 p.m. Oct. 31, 2014 - PR Newswire - PRF
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
Actavis Confirms Generic Quillivant XR® Patent Challenge 8:00 a.m. Oct. 16, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting 8:00 a.m. Oct. 9, 2014 - BusinessWire - BZX
EQUITY ALERT: Rosen Law Firm Announces Investigation of Durata Therapeutics, Inc. Concerning its Proposed Sale to Actavis plc – DRTX 11:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 11:34 a.m. Oct. 6, 2014 - PR Newswire - PRF
Actavis to Acquire Durata Therapeutics, Inc. 8:00 a.m. Oct. 6, 2014 - PR Newswire - PRF
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents 7:30 a.m. Oct. 2, 2014 - GlobeNewswire
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast 8:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Actavis Confirms Generic Butrans® Patent Challenge 4:05 p.m. Sept. 25, 2014 - PR Newswire - PRF
(0)
(0)Scroll down for more posts ▼